Loading
Latest filing published 18 Sept 2024 for Emmaus Life Sciences, Inc., €719.
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Seah H. Lim on record concern Emmaus Life Sciences, Inc. We count 8 filings; the first trade dates from 9 October 2022 and the latest from 16 September 2024.
Both buying and selling appear: 5 purchases worth €30k, against 2 sales worth €2,080. Taken together, the purchases exceed the sales by €28k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2024 alone, the filings show 1 purchase and no sales.
The median purchase comes to €2,744. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 4 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -7.5%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 18 September 2024: an open-market purchase of €719, in Emmaus Life Sciences, Inc. The median gap between a trade and its publication by SEC (Form 4) is 55 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations